FDA Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton as a Potential First-in-Class Therapy ...

— Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orexin 2 Receptor Agonist — In a separate oral ...

Japanese drugmaker Nxera Pharma today notes that UK based Centessa Pharmaceuticals has achieved an early development ...

Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, ...

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early ...

US FDA accepts and grants priority review status to Takeda’s oveporexton for the treatment of narcolepsy type 1: Osaka, Japan Wednesday, February 11, 2026, 12:00 Hrs [IST] Taked ...

ZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (NLS), a biopharmaceutical company, is pleased to share preclinical data demonstrating the ...

The US Food and Drug Administration (FDA) has accepted Takeda’s New Drug Application (NDA) and granted Priority Review for ...

TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house ...

The orexin deficit is believed to be the root cause of narcolepsy Mazindol ER is the most advanced Orexin-2 partial receptor agonist in development for the treatment of narcolepsy and other rare sleep ...

— Consistent, Dose-Dependent Effects Enable Dose Selection for Evaluation in Planned Phase 2 Study — The patients with NT1 were randomized to a crossover study in which each of them received 1 mg, 3 ...